Cyprotex
Lynn VerPlank has extensive experience in the scientific field, ranging from academia to industry. They specialize in in vitro ADME-Tox assay services and have managed multiple roles in various companies, including Cyprotex, Icagen, Broad Institute, and Harvard Medical School. With a Ph.D. in Molecular Microbiology and a BS in Molecular Biology, Lynn has a strong background in research and laboratory work, making significant contributions to the field of biology.
This person is not in the org chart
This person is not in any offices
Cyprotex
Founded in 1999, Cyprotex (www.cyprotex.com) has grown to become an industry leader in in vitro and in silico ADME-Tox. The company, with sites in the UK and USA, was acquired by Evotec (www.evotec.com) in 2016. The Evotec Group offer expert support from early discovery through to clinical development. * High-throughput ADME screening * Customised ADME assays * In silico ADME predictive modeling * In vitro toxicology